Published results reinforce a durable safety profile and align with multi-year outcomes across three prospective clinical studies and 10 peer-reviewed publications

Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, today announced the publication of long-term results from a multicenter study evaluating the safety and efficacy of RhinAer, which uses temperature-controlled radiofrequency (TCRF) to target the posterior nasal nerve (PNN) in patients with chronic rhinitis (CR). Published in the American Journal of Rhinology & Allergy, the study followed patients for three years post-treatment, reporting sustained improvements in symptoms, quality of life, and medication burden with no serious device- or procedure-related adverse events.

This publication, together with Cigna Healthcare’s recent decision to cover RhinAer treatment of the PNN (CPT 31242) effective September 15, 2025, reinforces the growing recognition of RhinAer’s clinical efficacy and net health benefit as a minimally invasive alternative to surgery or long-term clinic-based management.

The prospective, single-arm, open-label study enrolled 129 patients across 19 sites in the U.S. and Germany, and results demonstrated:

• Patients experienced a 58% improvement in total nasal symptom scores (rTNSS) at three years, consistent with the strong outcomes observed at three months.
• A 60% improvement in quality of life was observed at three years (p < 0.001), as measured by the MiniRQLQ score.
• Only 2 patients (1.6%) underwent a reintervention related to PNN ablation over the three-year period.
• No serious adverse events were associated with the procedure at any time during the three-year follow-up.

“With multiple studies demonstrating consistent, three-year outcomes, RhinAer continues to set the standard for durable, definitive, and comprehensive chronic rhinitis procedures,” said Matt Brokaw, President and CEO of Aerin Medical. “We’re proud to support ENT physicians with clinically proven, minimally invasive solutions that deliver lasting relief and elevate patient care.”

The study results align with prior data showing that TCRF ablation of the PNN offers clinically meaningful, long-term benefits for patients suffering from both allergic and nonallergic rhinitis. By targeting hyperactive nasal nerves and sources of congestion with precision, a single RhinAer procedure breaks the cycle of inefficient and costly in-clinic management.

“We now have three-year data showing that a single in-office RhinAer procedure can deliver sustained, meaningful relief from chronic rhinitis symptoms like nasal congestion, postnasal drip, and cough,” said Elina Toskala, MD, PhD, MBA Professor and Vice Chair at Thomas Jefferson University, Dept of Otolaryngology – Head and Neck Surgery, and co-investigator of the RELIEF study. “For patients who haven’t found success with medications, this offers an important option that can dramatically improve quality of life over the long term.”

About RhinAer

Using temperature-controlled, radiofrequency technology, RhinAer features a thin, wand-like stylus that is inserted via the nostril to deliver precise therapeutic benefits, while sparing surrounding tissues. RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, minimal to no downtime, and little discomfort. RhinAer initially received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit www.RhinAer.com.

About Aerin Medical

Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin’s mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company’s products, VivAer^® for nasal airway obstruction and RhinAer^® for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 175,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250904663672/en/